News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QR Pharma Receives FDA Clearance to Conduct Clinical Trials with Its Second Novel Alzheimer Compound, Bisnorcymserine


12/2/2010 10:41:12 AM

RADNOR, Pa.--(BUSINESS WIRE)--QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) to begin human clinical trials and evaluate the safety and efficacy of the company’s second product, bisnorcymserine (BNC). “Receiving clearance to move into clinical studies for BNC is a significant milestone for QR Pharma,” said Maria Maccecchini, CEO of QR Pharma.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES